KGKimberly A. Gudzune

Kimberly A. Gudzune

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kimberly A. Gudzune has a total of 249 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Development of program requirements for obesity medicine fellowship training in the U.S.

    by Stacy L. Schmidt, Amin Sabet, Denise H. Wong, Adam H. Gilden, Edmond P. Wickham, Sarah Raatz, Claudia K. Fox, Kimberly A. Gudzune


  • Open Access

    The long-term effectiveness of the anti-obesity medication phentermine (LEAP) trial: Rationale, design, and baseline characteristics

    by Caroline Blackwell Young, Emily Rives, Kimberly A. Gudzune, Byron C. Jaeger, Courtney G. Simmons, Brian N. White, Stephanie A. Hooker, Deborah B. Horn, Deborah R. Young, Jennifer Vesely, et al.


  • Open Access

    An obesity care curriculum improves residents’ self-efficacy and clinical practice habits

    by Marci Laudenslager, Kacey Chae, Sean Tackett, Amanda Bertram, Kimberly A. Gudzune


  • Open Access

    Application of the Lancet Commission Criteria for the Diagnosis of Obesity to a Clinical Trials Population: The LEAP Trial

    by Faith Anne N. Heeren, Kathleen R. Ruddiman, Courtney Simmons, Brian N. White, Byron C. Jaeger, Nicholas M. Pajewski, Stephanie A. Hooker, Deborah B. Horn, Katy Martin‐Fernandez, Kimberly A. Gudzune, et al.

    Objective: This study aimed to apply The Lancet Diabetes & Endocrinology criteria for diagnosing obesity among clinical trial participants and understand participants' characteristics by obesity status. Methods: The criteria were operationalized and applied to baseline data from the Long‐term Effectiveness of the Anti‐obesity medication Phentermine (LEAP) trial (NCT05176626). Excess adiposity, organ and tissue dysfunction, and limitations to daily activities were assessed. We examined differences between participants with “no obesity,” “pre‐clinical obesity,” and “clinical obesity.” Results: Among the 860 participants, 0.8% had no obesity (mean BMI 29.0 kg/m 2 [SD 0.6]), 18.7% had pre‐clinical obesity (mean BMI 35.2 kg/m 2 [SD 3.5]), and 80.5% had clinical obesity (mean BMI 35.9 kg/m 2 [SD 4.3]). Participants with no/pre‐clinical obesity had lower mean SF‐12 mental component scores and greater baseline engagement with weight control strategies compared to those with clinical obesity. Participants with clinical obesity were older and, by definition, had a greater burden of cardiometabolic risk factors. Conclusions: Among clinical trial participants eligible for obesity pharmacotherapy, 19.5% were classified as having no/pre‐clinical obesity using the Lancet criteria. Applying the criteria was complicated in a well‐resourced trial setting, which suggests potential challenges in implementing these guidelines in real‐world practice.


  • An Update on the American Board of Obesity Medicine ( ABOM ): 2017–2024

    by Brianna Johnson‐Rabbett, Tirissa J. Reid, Edmond P. Wickham, Judith Korner, Dana R. Brittan, Kimberly A. Gudzune

    Objective: This study aimed to describe the characteristics of American Board of Obesity Medicine (ABOM) physician diplomates over the last 8 years (2017–2024). Methods: Using the ABOM database, we conducted a cross‐sectional study of physicians who achieved initial ABOM certification between 2017 and 2024. Characteristics included demographics, primary medical specialty, years of obesity medicine experience, patient population, and practice setting. We conducted descriptive analyses and compared current characteristics with estimates extracted from the published ABOM 5‐year report (2012–2016). Results: Overall, 8640 physicians achieved initial ABOM certification between 2017 and 2024; 2068 achieved certification between 2012 and 2016. Between the 2012–2016 and 2017–2024 groups, notable differences were increases in physicians under age 40 years (22.7% vs. 47.6%, respectively), women (52.8% vs. 64.0%, respectively), and practicing obesity medicine for less than 2 years at initial certification (40.2% vs. 68.3%, respectively). The most common primary medical specialties were internal medicine (32.4%), family medicine (29.2%), and internal medicine subspecialties (14.2%). Conclusions: We found that recent ABOM diplomates are likely entering the field earlier in their careers and with fewer years of obesity medicine experience than the initial group. Future investigation is needed to understand how ABOM and other obesity organizations can best support these physicians in their transition to obesity medicine clinical practice.


  • Open Access

    Developing and implementing an obesity medicine fellowship program: Experience at a U.S. academic medical center

    by Zoobia W. Chaudhry, Marci Laudenslager, Kimberly A. Gudzune, Selvi Rajagopal


  • Open Access

    Reimagining primary care visits for people living with obesity: A Co-design and validation study

    by Kristal Lyn Brown, Gwyn Cready, Katie Schmiedicker, Michelle Vicari, James Zervios, Theodore K. Kyle, Kimberly A. Gudzune


  • Open Access

    Perceptions of anti‐obesity medications among people with obesity and healthcare providers in the US: Findings from the OBSERVE Study

    by Lee M. Kaplan, Kimberly Gudzune, Jamy Ard, Rekha Kumar, Nadia N. Ahmad, Hong Kan, Tracy J. Sims, Jiat Ling Poon, Kristen King‐Concialdi, Kathleen Beusterien, et al.

    Objective: The objective of this study was to understand the perceptions of and drivers/barriers to antiobesity medication (AOM) use among people with obesity (PwO) and health care providers (HCPs) in the United States.Methods: In 2022, PwO and HCPs completed cross‐sectional surveys that included questions on perceptions of obesity management and AOMs. Data were analyzed using descriptive statistics.Results: Survey participants (1007 PwO and 474 HCPs) emphasized the effectiveness of lifestyle change and the patient's responsibility to address obesity. PwO reported a willingness to take newly approved AOMs long term. HCPs believed that their patients would adhere to AOMs long term if they experienced success. Both PwO and HCPs perceived an increased effectiveness of a multimodal approach to combining AOMs with HCP‐guided lifestyle intervention. Potential barriers to long‐term use of AOMs for both groups included concerns regarding long‐term side effects and outcomes, costs and insurance coverage, and perception of AOMs that do not align with treatment of a chronic disease.Conclusions: PwO and HCPs are interested in new AOM options, but educational gaps remain as a barrier to recommended multimodal chronic care. Ongoing education that includes the known effectiveness and safety data of newer AOMs and pending outcome trials could improve shared decision‐making in obesity care.


  • Open Access

    Centering Weight Management Clinical Decision Support in Primary Care on Patients With Obesity and Practitioners: A Proof‐Of‐Concept Study

    by Kimberly A. Gudzune, Jessica L. Schwartz, Kelly Olsson, Erik Almazan, Thomas Grader Beck, Jyotsna Ghosh, Wendy L. Bennett, Jeanne M. Clark

    Background: Clinical decision support systems (CDSS) are electronic health record tools that support practitioners' decision‐making at the point‐of‐care. CDSS may aid clinical care but are not often centered on patients or practitioners.Aims: To develop and preliminarily test a CDSS designed to support evidence‐based obesity treatment, promote a patient‐centered experience, and integrate with clinical workflows.Materials & Methods: The CDSS allowed patients to complete a pre‐visit questionnaire via the patient portal, which activated multiple elements for the primary care practitioner (PCP). A 3‐month proof‐of‐concept study was conducted among 10 PCPs at 5 clinics to determine usefulness, usability, and acceptability through validated surveys (mean score ≥ 2.5 signified positive outcome; max 5). Using t‐tests, pre‐post differences in PCPs' frequency of self‐reported clinical practices (1‐never; 5‐always) were examined.Results: Most PCPs were physicians with mean experience of 10.8 years (SD 7.5). Overall, mean scores for usefulness, usability, and acceptability were 3.2 (SD 0.8), 3.5 (SD 0.9), and 3.6 (SD 0.9), respectively. PCPs reported significant increases in three key clinical practices—counseling on behavioral interventions (3.1 vs. 3.9 [p < 0.01]), referring to weight‐loss programs (2.8 vs. 3.5 [p < 0.01]), and discussing anti‐obesity medications (3.3 vs. 3.8 [p = 0.02]).Conclusion: This weight management CDSS was useful and usable for PCPs and improved obesity‐related practice habits. Future studies need to evaluate its impact on patient outcomes.